Barclays PLC Sells 27,790 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Barclays PLC decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 21.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,058 shares of the company's stock after selling 27,790 shares during the quarter. Barclays PLC owned 0.12% of CRISPR Therapeutics worth $4,017,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently made changes to their positions in CRSP. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics in the 3rd quarter worth approximately $40,000. Franklin Resources Inc. increased its stake in shares of CRISPR Therapeutics by 12.7% in the third quarter. Franklin Resources Inc. now owns 7,097 shares of the company's stock worth $339,000 after buying an additional 800 shares during the period. Nordea Investment Management AB raised its holdings in CRISPR Therapeutics by 4.4% during the 4th quarter. Nordea Investment Management AB now owns 125,400 shares of the company's stock valued at $4,913,000 after buying an additional 5,300 shares during the last quarter. Capital Market Strategies LLC purchased a new stake in CRISPR Therapeutics during the 4th quarter valued at $461,000. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in CRISPR Therapeutics by 19.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 36,139 shares of the company's stock worth $1,422,000 after acquiring an additional 5,898 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.

Analyst Upgrades and Downgrades

CRSP has been the subject of a number of analyst reports. The Goldman Sachs Group dropped their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. Truist Financial increased their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Chardan Capital decreased their target price on CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a report on Thursday, February 13th. Needham & Company LLC reiterated a "buy" rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, April 9th. Finally, Royal Bank of Canada decreased their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $73.11.

Insider Buying and Selling at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 2,850 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the sale, the general counsel now owns 77,530 shares of the company's stock, valued at $3,288,822.60. The trade was a 3.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,381 shares of company stock worth $1,608,243. Insiders own 4.10% of the company's stock.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock traded up $1.27 during trading on Wednesday, hitting $38.67. 2,082,025 shares of the company's stock traded hands, compared to its average volume of 1,641,973. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $67.88. The business has a 50-day simple moving average of $39.46 and a 200-day simple moving average of $43.39. The stock has a market capitalization of $3.34 billion, a P/E ratio of -8.85 and a beta of 1.85.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.